Business Context and Reporting Period
Syndax Pharmaceuticals Inc. filed this Form 8-K on February 4, 2020, reporting events occurring on January 30, 2020. The company is a Delaware corporation focused on life sciences, with its principal executive offices in Waltham, Massachusetts.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics include:
- Offering Proceeds: Approximately $35.0 million in aggregate gross proceeds.
- Securities Issued: 3,036,719 shares of Common Stock and pre-funded warrants to purchase 1,338,287 shares.
- Offering Price: $8.00 per share for Common Stock; $7.9999 per Pre-Funded Warrant.
- Investors: Five leading life sciences investors, including Biotechnology Value Fund, L.P., Boxer Capital, and AI Life Sciences Investments LLC.
- Underwriting: No underwriter or placement agent participated.
The filing does not provide current revenue, profit, cash flow, margins, or debt levels. Investors should refer to the company's most recent Form 10-K for operational financial data.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement, resulting in a significant increase in the company's cash liquidity through the issuance of new equity and pre-funded warrants. Additionally, the company filed updated business information and risk factors via a prospectus supplement on February 3, 2020, to supplement disclosures in its prior filings.
Guidance, Outlook, and Risks
Management commentary is limited to the description of the transaction terms. The filing references updated risk factors incorporated by reference from a prospectus supplement filed on February 3, 2020. No specific financial guidance or outlook for future periods is provided in this document.
Investor Verification Checklist
- Verify the final closing date and actual cash proceeds received from the $35.0 million offering.
- Review the "Updated Company Disclosures" (Exhibit 99.1) for new risk factors affecting the business.
- Confirm the dilution impact of the 3,036,719 new shares and potential exercise of 1,338,287 pre-funded warrants.
- Check the company's most recent Form 10-K for current cash burn rates and liquidity position prior to this capital raise.